Aikaterini Tsiogka

Dr. Aikaterini Tsiogka


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ATAikaterini Tsiogka
Aikaterini Tsiogka
MKMARIA KYRIAZOPOULOU
MARIA KYRIAZOPOULOU
GKGeorge Kontochristopoulos
George Kontochristopoulos
ENElectra Nicolaidou
Electra Nicolaidou
ASAlexandros Stratigos
Alexandros Stratigos
Stamatis GregoriouStamatis Gregoriou
Stamatis Gregoriou
In recent years, the broadening understanding of the pathogenesis of atopic dermatitis (AD) has led to the development of novel therapeutic molecules, that target core inflammatory components of the disease. The Janus kinase (JAK)/signal transducer and activation of transcription (STAT) pathway constitutes the principal signaling cascade for a large number of cytokines and growth factors and is involved in intracellular signal transduction and subsequent regulation of gene transcription. Current knowledge suggests that the robust activation of the T-helper (Th)-2 [interleukin (IL)-4, IL-5, IL-13, IL-31] and Th22 (IL-22) immune responses in both skin and serum plays a pivotal role in the immunopathogenesis of AD especially at the acute stage, followed by a variable degree of Th1 (interferon-γ, tumor necrosis factor alpha) and Th17 (IL-17) activation in chronic disease. Of note, most of the aforementioned inflammatory cytokines utilize the JAK/STAT pathway for downstream signal transduction, explaining the emerging role of JAK inhibitors in the therapeutic armamentarium of AD. The present systematic review aims to discuss the involvement of JAK/STAT pathway in the pathogenesis of AD and summarize the clinical data available on the efficacy and safety of JAK inhibitors which have been used in the treatment of AD thus far.

1 June 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
GKGudula Kirtschig
Gudula Kirtschig
MKM. Kinberger
M. Kinberger
AKA. Kreuter
A. Kreuter
RSR. Simpson
R. Simpson
AGA. Günthert
A. Günthert
RWR. N. Werner
R. N. Werner

20 January 2021 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
ATAikaterini Tsiogka
Aikaterini Tsiogka
JBJ Bauer
J Bauer
APA Patsatsi
A Patsatsi
Bullous pemphigoid constitutes a rare dermatological immune-related adverse event of programmed cell...

1 June 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
GKGudula Kirtschig
Gudula Kirtschig
MKM. Kinberger
M. Kinberger
AKA. Kreuter
A. Kreuter
RSR. Simpson
R. Simpson
AGA. Günthert
A. Günthert
RWR. N. Werner
R. N. Werner

Verified
Journal Article
Open access
PDF file
ZAZACHAROPOUOU AIKATERINI
ZACHAROPOUOU AIKATERINI
ATAikaterini Tsiogka
Aikaterini Tsiogka
ATAntonios Tsimpidakis
Antonios Tsimpidakis
ALAndroniki Lamia
Androniki Lamia
Dimitra KoumakiDimitra Koumaki
Dimitra Koumaki
Stamatis GregoriouStamatis Gregoriou
Stamatis Gregoriou
Tinea incognito is a dermatophyte infection with atypical features, due to the use of topical or systemic steroids or other immunosuppressive medications. Delayed diagnosis, spread of the infection to critical body surfaces, resistance to antifungal drugs, and increased costs due to prolonged hospitalization and multiple treatment regimens often complicate tinea incognito. It can affect individuals of all ages and genders, but it is more common in children. Atypical clinical appearance often necessitates differentiation from other diseases such as eczema, seborrheic dermatitis, lupus erythematosus, psoriasis, or other non-fungal skin conditions. The treatment of tinea incognito usually involves discontinuation of topical steroids or other immunosuppressive medications. Preventive measures and management of the underlying fungal infection are necessary and can be achieved with antifungal drugs. Patients should wear loose cotton clothes, use boiling water for laundry, and iron their clothing before wearing them. Additionally, they should avoid sharing bed linens, towels, clothes, and shoes. This review aims to raise awareness of tinea incognito among health practitioners, provide tips for detecting the disorder, include it in the differentials, and evaluate the available diagnostic procedures.

16 April 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ATAikaterini Tsiogka
Aikaterini Tsiogka
Dimitra KoumakiDimitra Koumaki
Dimitra Koumaki
MKMARIA KYRIAZOPOULOU
MARIA KYRIAZOPOULOU
KLKonstantinos Liopyris
Konstantinos Liopyris
ASAlexandros Stratigos
Alexandros Stratigos
Stamatis GregoriouStamatis Gregoriou
Stamatis Gregoriou
Eccrine porocarcinoma (EPC) constitutes a rare malignant adnexal tumor, which accounts for about 0.005–0.01% of all cutaneous malignancies. It may develop de novo or arise from an eccrine poroma, after a latency period of years or even decades. Accumulating data suggest that specific oncogenic drivers and signaling pathways may be implicated in its tumorigenesis, while recent data have demonstrated a high overall mutation rate attributed to UV exposure. Diagnosis may be challenging and should rely on the combination of clinical, dermoscopical, histopathological and immunohistochemical findings. The literature is controversial regarding tumor behavior and prognosis and, therefore, there is no consensus on its surgical management, utility of lymph-node biopsy and further adjuvant or systemic treatment. However, recent advances in tumorigenesis of EPC may aid in the development of novel treatment strategies, which could improve survival of advanced or metastatic disease, such as immunotherapy. This review presents an update of the epidemiology, pathogenesis and clinical presentation of EPC and summarizes current data on diagnostic evaluation and management of this rare cutaneous malignancy.